Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

3rd Immunotherapy of Cancer Conference (ITOC3) /
Targeting tumour vasculature by DNA vaccines

21st - 23rd Mar 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.04.16
Views: 2090

Dr Andrea Facciabene - University of Pennsylvania, Philadelphia, USA

Dr Facciabene (University of Pennsylvania, Philadelphia, USA) talks to ecancertv at ITOC3 about novel TEM-1 vaccines.

The vaccine targets Tumour Endothelial Marker 1, eliminating tumour vasculature and inducing a secondary immune response.

The trials have proven effective in models of breast cancer, Lewis lung carcinoma, cervical cancer and colorectal cancer.

Host angiogenesis in wound healing and pregnancy is unaffected by the vaccine.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation